The spectrum of use of rituximab in chronic lymphocytic leukemia

The monoclonal chimeric anti-CD20 antibody, rituximab, has considerably improved therapeutic outcome in B-cell chronic lymphocytic leukemia. Rituximab has limited clinical activity when used as a single agent. The combination of the monoclonal antibody with fludarabine-based regimens clearly demonst...

Descripción completa

Detalles Bibliográficos
Autores principales: Tedeschi, Alessandra, Vismara, Eleonora, Ricci, Francesca, Morra, Enrica, Montillo, Marco
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024887/
https://www.ncbi.nlm.nih.gov/pubmed/21289858
http://dx.doi.org/10.2147/OTT.S8151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024887/
https://www.ncbi.nlm.nih.gov/pubmed/21289858
http://dx.doi.org/10.2147/OTT.S8151

Ejemplares similares